ADMA Biologics Inc.
ADMA | NASDAQ
$9.74
+$0.23 (+2.47%)
Sep 22, 2026, 11:50 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 29.42 | 20.18 | -34.77 | -9.02 | -2.31 | -1.91 |
PEG Ratio | -1.09 | -0.03 | 0.50 | 0.31 | 0.06 | 0.67 |
PS Ratio | 8.52 | 9.37 | 3.92 | 4.98 | 2.43 | 3.98 |
PB Ratio | 9.11 | 11.45 | 7.49 | 5.05 | 1.39 | 1.90 |
P/FCF Ratio | 156.23 | 36.31 | 265.09 | -10.46 | -1.56 | -1.46 |
P/OCF Ratio | 86.25 | 33.68 | 115.04 | -12.90 | -1.75 | -1.65 |
OCF/S Ratio | 9.88 | 27.83 | 3.41 | -38.62 | -138.82 | -241.60 |
Debt / Equity Ratio | 0.17 | 0.24 | 1.05 | 1.02 | 0.73 | 1.11 |
Quick Ratio | 3.74 | 2.90 | 1.69 | 2.73 | 2.77 | 3.62 |
Current Ratio | 6.71 | 5.97 | 5.16 | 6.89 | 6.87 | 7.71 |
Asset Turnover | 0.82 | 0.87 | 0.78 | 0.44 | 0.29 | 0.20 |
Interest Coverage | 26.93 | 9.98 | 0.86 | -2.04 | -4.47 | -5.42 |
Return on Equity | 30.78% | 56.64% | -20.89% | -43.37% | -50.75% | -85.83% |
Return on Assets | 23.54% | 40.45% | -8.58% | -18.91% | -25.94% | -36.47% |
Return on Invested Capital | 27.57% | 32% | 7.71% | -12.69% | -23.68% | -34.51% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 57.39% | 51.48% | 34.44% | 22.89% | 1.45% | -45.17% |
Net Profit Margin | 28.80% | 46.35% | -10.94% | -42.77% | -88.52% | -179.41% |
Pretax Profit Margin | 35.80% | 29.48% | -10.94% | -42.77% | -88.52% | -179.41% |
Operating Profit Margin | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% | -153.75% |
FCF Margin | 5.45% | 25.82% | 1.48% | -47.65% | -155.52% | -271.74% |
EBITDA Margin | 38.78% | 34.63% | 1.98% | -25.64% | -65.60% | -141.69% |
Add to Watchlist
Select watchlists to add or remove ADMA